Jefferies Reiterates Bullish Stance On Seattle Genetics (SGEN) Related To Eventual Adcentris Label

Jefferies reiterated their Buy rating and $22 price target on Seattle Genetics (NASDAQ: SGEN) saying favorable change in Adcentris program bodes well for eventual label.

The firm states, "We learned of a new protocol amendment being implemented for the Adcentris expanded access program in the U.S. to allow second-line, pre-transplant patients to participate. We view this as a positive signal of the potential for Adcentris to receive a broad FDA label that covers second-line Hodgkin lymphoma in addition to the third-line and salvage population treated in the pivotal trial."


For more ratings news on Seattle Genetics click here and for the rating history of Seattle Genetics click here.

Shares of Seattle Genetics closed at $18.94 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cummins (CMI) PT Lowered to $675 at Jefferies
• Benchmark Reiterates Buy Rating on Rank One Computing (ROC)
• Deere (DE) PT Raised to $585 at JPMorgan